FDA examines cause of valsartan impurity
The US Food and Drug Administration (FDA) says a “major operation” is underway to investigate and address the “troubling finding” of a toxic impurity in some generic versions of valsartan that could cause cancer, leading the agency to also test all drugs in valsartan’s therapeutic class for traces of the toxic material.
You may also be interested in...
Release of several different safety announcements showcases US FDA Commissioner Gottlieb's efforts to quell potential public concerns with an active communication strategy.
Keeping Track: StrataGraft Continues US FDA’s Biologic Center Approvals Streak; Another CRL For Avenue’s Tramadol IV
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Sens. Durbin and Grassley hope report will help revive their flagging legislation that would require Rx ads to include list prices Senators claim that the Government Accountability Office concludes that direct-to-consumer spots for prescription drugs drives ‘drastic’ increases in Medicare costs.